These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26287854)

  • 61. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
    Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
    Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives.
    Fitzgerald G; Kiernan T
    Expert Rev Cardiovasc Ther; 2018 Aug; 16(8):567-578. PubMed ID: 29979908
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Into the future: diversifying lipid management.
    Tonkin AM; Watts GF
    Lancet; 2012 Dec; 380(9858):1971-4. PubMed ID: 23141810
    [No Abstract]   [Full Text] [Related]  

  • 65. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
    Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Unmet needs: patients with statin intolerance or familial hypercholesterolemia].
    Masana L; Civeira F
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():22-30. PubMed ID: 27888902
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
    Miyoshi T; Nakamura K; Doi M; Ito H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Increased statin dose could mean a 22% decrease in vascular events. Even patients with low baseline LDL can benefit from increased doses.
    Duke Med Health News; 2011 Jan; 17(1):3. PubMed ID: 21313727
    [No Abstract]   [Full Text] [Related]  

  • 71. Alirocumab for the treatment of hypercholesterolaemia.
    Della Pepa G; Bozzetto L; Annuzzi G; Rivellese AA
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):571-582. PubMed ID: 28395555
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.
    Barter PJ; Rye KA
    Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953
    [No Abstract]   [Full Text] [Related]  

  • 73. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
    White CM
    Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Considerable LDL lowering is advantageous].
    MMW Fortschr Med; 2005 Sep; 147(35-36):9. PubMed ID: 16180563
    [No Abstract]   [Full Text] [Related]  

  • 75. More than a statin.
    Underwood A
    Newsweek; 2004 Aug; 144(6):54. PubMed ID: 15449505
    [No Abstract]   [Full Text] [Related]  

  • 76. [Hypercholesterolemia: when statins are not enough or not tolerated. With combination therapy to LDL cholesterol target goal].
    MMW Fortschr Med; 2012 Jul; 154(13):86-7. PubMed ID: 22957390
    [No Abstract]   [Full Text] [Related]  

  • 77. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
    Saußele T
    Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 79. Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit.
    Mitka M
    JAMA; 2010 Jan; 303(3):211-2. PubMed ID: 20085945
    [No Abstract]   [Full Text] [Related]  

  • 80. PCSK9 inhibitors--past, present and future.
    Reiner Ž
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1517-21. PubMed ID: 26329686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.